Your browser is no longer supported. Please, upgrade your browser.
ZFGN Zafgen, Inc. daily Stock Chart
ZFGN [NASD]
Zafgen, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own9.98% Shs Outstand36.77M Perf Week-7.69%
Market Cap44.12M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float33.65M Perf Month0.84%
Income-52.70M PEG- EPS next Q-0.23 Inst Own66.40% Short Float2.45% Perf Quarter54.82%
Sales- P/S- EPS this Y-0.40% Inst Trans8.89% Short Ratio1.23 Perf Half Y39.53%
Book/sh1.60 P/B0.75 EPS next Y32.00% ROA-49.20% Target Price- Perf Year-75.21%
Cash/sh2.23 P/C0.54 EPS next 5Y- ROE-68.60% 52W Range0.62 - 4.99 Perf YTD8.11%
Dividend- P/FCF- EPS past 5Y-22.70% ROI- 52W High-75.95% Beta-0.22
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low93.55% ATR0.10
Employees38 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)48.22 Volatility7.33% 7.84%
OptionableYes Debt/Eq0.29 EPS Q/Q16.00% Profit Margin- Rel Volume0.26 Prev Close1.20
ShortableYes LT Debt/Eq0.17 EarningsMar 09 AMC Payout- Avg Volume671.98K Price1.20
Recom3.00 SMA20-1.19% SMA505.47% SMA2008.64% Volume122,471 Change0.00%
Apr-26-19Initiated ROTH Capital Buy $8
Jul-03-18Initiated Piper Jaffray Overweight
Apr-20-17Initiated ROTH Capital Buy $9
Jan-06-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jul-20-16Downgrade FBR Capital Outperform → Mkt Perform $20 → $5
Mar-10-16Reiterated RBC Capital Mkts Outperform $21 → $19
Jan-21-16Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $21
Jan-21-16Upgrade FBR Capital Mkt Perform → Outperform $9 → $20
Dec-03-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
Dec-03-15Downgrade Leerink Partners Outperform → Mkt Perform
Dec-02-15Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $7
Nov-13-15Reiterated Canaccord Genuity Buy $53 → $30
Oct-19-15Reiterated RBC Capital Mkts Outperform $46 → $20
Oct-19-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-16-15Downgrade FBR Capital Outperform → Mkt Perform $48 → $16
Oct-15-15Reiterated RBC Capital Mkts Outperform $58 → $46
Oct-15-15Reiterated FBR Capital Outperform $60 → $48
Jun-17-15Initiated Sun Trust Rbsn Humphrey Buy $47
May-13-15Reiterated Canaccord Genuity Buy $58 → $53
Jan-23-15Initiated RBC Capital Mkts Outperform $53
Dec-30-19 02:26PM  5 Deep-Value Stocks for 2020 GuruFocus.com -5.17%
Dec-19-19 07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 06:00AM  Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement GlobeNewswire -13.12%
Dec-14-19 08:04PM  Is Zafgen Inc (ZFGN) A Good Stock To Buy? Insider Monkey
Nov-06-19 04:01PM  Zafgen Reports Third Quarter 2019 Financial Results GlobeNewswire
Sep-20-19 02:55PM  Zafgen plans deeper cuts to workforce after another FDA setback American City Business Journals
Aug-08-19 04:15PM  Zafgen Reports Second Quarter 2019 Operating and Financial Results GlobeNewswire
Aug-06-19 04:15PM  Zafgen to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-24-19 04:15PM  Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061 GlobeNewswire
Jul-18-19 01:17PM  How Many Zafgen, Inc. (NASDAQ:ZFGN) Shares Do Institutions Own? Simply Wall St.
Jun-25-19 09:45PM  Is Zafgen Inc (ZFGN) A Good Stock To Buy? Insider Monkey
Jun-13-19 04:15PM  Zafgen to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-10-19 07:00AM  Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions GlobeNewswire
May-30-19 10:44AM  Micro-Cap Biotech Zafgen Plunges To Record Low: What You Need To Know Benzinga -20.08%
07:00AM  Zafgen Announces Regulatory Update on ZGN-1061 GlobeNewswire
May-09-19 07:04PM  Zafgen: 1Q Earnings Snapshot Associated Press
04:15PM  Zafgen Reports First Quarter 2019 Operating and Financial Results GlobeNewswire
May-02-19 04:30PM  Zafgen to Announce First Quarter 2019 Financial Results GlobeNewswire
Apr-04-19 04:30PM  Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-02-19 06:23PM  Edited Transcript of ZFGN earnings conference call or presentation 11-Mar-19 9:00pm GMT Thomson Reuters StreetEvents
04:41PM  Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc. PR Newswire
Mar-30-19 08:00PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors GlobeNewswire
Mar-27-19 05:46PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zafgen, Inc. Investors Business Wire
Mar-26-19 05:16PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors GlobeNewswire
Mar-15-19 08:50PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors Business Wire
03:55PM  What Do Investors Need To Know About Zafgen, Inc.s (NASDAQ:ZFGN) Growth? Simply Wall St.
Mar-13-19 05:00PM  Zafgen to Present at the 31st Annual ROTH Conference GlobeNewswire
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
Mar-12-19 07:47AM  The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug Benzinga -37.17%
05:47AM  Zafgen shelves another drug; chief medical officer exits American City Business Journals
Mar-11-19 04:48PM  Zafgen: 4Q Earnings Snapshot Associated Press
04:05PM  Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates GlobeNewswire
Mar-07-19 08:00AM  Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-06-19 06:00PM  Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Mar-04-19 07:00AM  Zafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development GlobeNewswire
Jan-17-19 02:08PM  Latest data on Zafgen's diabetes pill does little to soothe investors American City Business Journals
07:00AM  Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061 GlobeNewswire
Jan-14-19 06:06AM  Zafgen Enters Oversold Territory Zacks
Dec-18-18 02:35AM  Zafgen Inc (ZFGN): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-13-18 08:32AM  Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey
Dec-07-18 04:52PM  CURRENT SHAREHOLDERS: Zamansky LLC Investigates Zafgen (ZFGN) for Potential Breaches of Fiduciary Duties Business Wire
Dec-04-18 09:38AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investigation of Zafgen, Inc. (ZFGN) ACCESSWIRE
Dec-03-18 05:06PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zafgen, Inc. ZFGN GlobeNewswire
Nov-28-18 11:19AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zafgen, Inc. - ZFGN PR Newswire -5.33%
08:22AM  Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News Zacks
Nov-27-18 05:47PM  Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial Zacks
04:28PM  Zafgen: Bargain or Busted? GuruFocus.com
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investigation of Zafgen, Inc. (ZFGN) GlobeNewswire
09:44AM  Company News For Nov 27, 2018 Zacks
06:50AM  Today's Research Reports on Trending Tickers: Zafgen and Edge Therapeutics ACCESSWIRE
Nov-26-18 04:37PM  Why Aurora Cannabis, Zafgen, and Overstock.com Slumped Today Motley Fool -40.55%
12:15PM  Why Zafgen Stock Is Crashing Today Motley Fool
10:27AM  Zafgen shares cut in half after FDA halts diabetes drug trial American City Business Journals
07:27AM  U.S. FDA puts Zafgen's diabetes trial on hold Reuters
07:07AM  Zafgen's IND for diabetes treatment placed on hold by FDA MarketWatch
07:00AM  Zafgen Provides Update on Investigational New Drug Application for ZGN-1061 GlobeNewswire
Nov-21-18 04:05PM  Zafgen to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-19-18 05:32PM  Edited Transcript of ZFGN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -5.67%
Nov-07-18 04:05PM  Zafgen Reports Third Quarter 2018 Operating and Financial Results GlobeNewswire
Nov-06-18 04:05PM  Zafgen to Present at the Stifel 2018 Healthcare Conference GlobeNewswire
Nov-01-18 08:00AM  Zafgen to Host Conference Call to Discuss Third Quarter 2018 Financial Results GlobeNewswire
Oct-04-18 07:00AM  Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference GlobeNewswire
Sep-28-18 03:45PM  Who Owns Zafgen Inc (NASDAQ:ZFGN)? Simply Wall St.
Sep-26-18 02:27PM  Amarin and Square are among the most important stock charts to watch MarketWatch
Aug-08-18 04:05PM  Zafgen to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-18 07:04PM  Zafgen: 2Q Earnings Snapshot Associated Press
04:05PM  Zafgen Reports Second Quarter 2018 Operating and Financial Results GlobeNewswire
02:30PM  Zafgen, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 07:52AM  The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings Benzinga -8.29%
Aug-02-18 04:05PM  Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes GlobeNewswire
Aug-01-18 04:15PM  Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-31-18 04:05PM  Zafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results GlobeNewswire
Jul-19-18 10:26AM  Harry Boxers three drug stocks to watch MarketWatch
Jul-09-18 08:00AM  Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study GlobeNewswire
Jul-05-18 08:54AM  Zafgen (ZFGN) Surges: Stock Moves 9.2% Higher Zacks
Jul-02-18 04:05PM  Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters Option to Purchase Additional Common Shares GlobeNewswire -6.65%
Jun-30-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-28-18 04:17PM  Here's Why Zafgen Inc. Rose by Double Digits Today Motley Fool +12.94%
08:00AM  Zafgen Announces Pricing of Offering of Common Stock GlobeNewswire
Jun-27-18 04:01PM  Zafgen Announces Proposed Offering of Common Stock GlobeNewswire
Jun-26-18 08:00AM  Today's Research Reports on Trending Tickers: Exelixis and Zafgen ACCESSWIRE
Jun-25-18 07:05AM  Zafgen Set to Join Russell 3000® Index GlobeNewswire +26.80%
07:00AM  REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call GlobeNewswire
Jun-23-18 10:00AM  Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes GlobeNewswire
Jun-17-18 04:16PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-07-18 07:00AM  Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors GlobeNewswire
May-30-18 07:00AM  Zafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer GlobeNewswire +10.84%
May-09-18 05:13AM  Zafgen: 1Q Earnings Snapshot Associated Press -12.16%
May-08-18 04:05PM  Zafgen Reports First Quarter 2018 Operating and Financial Results GlobeNewswire +5.71%
May-02-18 04:30PM  Zafgen to Present at Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
May-01-18 04:30PM  Zafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results GlobeNewswire
Mar-07-18 04:30PM  Zafgen to Present at Cowen 38th Annual Health Care Conference GlobeNewswire
12:24PM  Here's Why Zafgen Inc Rose as Much as 21.1% Today Motley Fool
Mar-06-18 05:15PM  Zafgen reports 4Q loss Associated Press
04:05PM  Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes GlobeNewswire
Mar-01-18 04:30PM  Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-08-18 04:00PM  Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-08-18 07:30AM  Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates Outlook ACCESSWIRE
Jan-05-18 07:00AM  Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018 GlobeNewswire
Nov-07-17 05:46PM  Zafgen reports 3Q loss Associated Press
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and liver diseases. Its lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase II clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. The company also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS; and ZGN-1345, an orally dosed MetAP2 inhibitor specifically targeting the liver. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.